Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R. Hoffmann VS, et al. Among authors: steegmann jl. Leukemia. 2015 Jun;29(6):1336-43. doi: 10.1038/leu.2015.73. Epub 2015 Mar 18. Leukemia. 2015. PMID: 25783795
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
Pérez-Lamas L, de Paz Arias R, Díaz RMA, Montero LFC, Payer ÁR, Sierra M, Marín FF, López RP, Cirici BX, Steegmann JL, Gómez Casares MT, Martínez-López J, García-Gutiérrez V. Pérez-Lamas L, et al. Among authors: steegmann jl. Ann Hematol. 2024 Apr 3. doi: 10.1007/s00277-024-05662-7. Online ahead of print. Ann Hematol. 2024. PMID: 38568260
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Mosquera-Orgueira A, Pérez-Encinas M, Hernández-Sánchez A, González-Martínez T, Arellano-Rodrigo E, Martínez-Elicegui J, Villaverde-Ramiro Á, Raya JM, Ayala R, Ferrer-Marín F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vázquez MI, García-Fortes M, Angona A, Cuevas B, Senín MA, Ramírez-Payer A, Ramírez MJ, Pérez-López R, González de Villambrosía S, Martínez-Valverde C, Gómez-Casares MT, García-Hernández C, Gasior M, Bellosillo B, Steegmann JL, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC. Mosquera-Orgueira A, et al. Among authors: steegmann jl. Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan. Hemasphere. 2022. PMID: 36570691 Free PMC article.
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, Raya JM, Pérez-Encinas M, Ayala R, Ferrer-Marín F, Velez P, Mora E, Fox ML, Hernández-Rivas JM, Xicoy B, Mata-Vázquez MI, García-Fortes M, Pérez-López R, Angona A, Cuevas B, Senín A, Ramírez MJ, Ramírez-Payer A, Gómez-Casares MT, Martínez-Valverde C, Magro E, Steegmann JL, Durán MA, García-Hernández C, Gasior M, de Villambrosia SG, Alvarez-Larrán A, Pereira A; Spanish MPN Group (GEMFIN). Hernández-Boluda JC, et al. Among authors: steegmann jl. Br J Haematol. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. Epub 2022 Sep 12. Br J Haematol. 2022. PMID: 36089912
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Pérez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jiménez-Velasco A, Lakhwani S, Casado LF, Rosell A, Escola A, Fernández MJ, Garcia-Hernandez C, Cervero C, Mora E, Sagüés M, Suarez-Varela S, Vélez P, Carrascosa Mastell P, Bitaube RF, Serrano L, Cortes M, Vera Goñi JA, Steegmann JL, de Soria VGG, Alonso-Dominguez JM, Araujo MC, Coll AP, Hernandez-Boluda JC, García-Gutiérrez V. Luna A, et al. Among authors: steegmann jl. Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23. Ann Hematol. 2022. PMID: 35997804 Free PMC article.
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
Vigón L, Luna A, Galán M, Rodríguez-Mora S, Fuertes D, Mateos E, Piris-Villaespesa M, Bautista G, San José E, Rivera-Torres J, Steegmann JL, de Ory F, Pérez-Olmeda M, Alcamí J, Planelles V, López-Huertas MR, García-Gutiérrez V, Coiras M. Vigón L, et al. Among authors: steegmann jl. J Clin Med. 2020 Dec 25;10(1):42. doi: 10.3390/jcm10010042. J Clin Med. 2020. PMID: 33375572 Free PMC article.
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
Ottmann OG, Stegelmann F, Breccia M, Steegmann JL, Olavarria E, Aimone P, Lipton JH. Ottmann OG, et al. Among authors: steegmann jl. Leuk Lymphoma. 2021 Mar;62(3):739-742. doi: 10.1080/10428194.2020.1839649. Epub 2020 Nov 6. Leuk Lymphoma. 2021. PMID: 33153366 Clinical Trial. No abstract available.
Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognostic factor.
Llamas-Velasco M, Ovejero-Merino E, García-Diez A, Requena L, Daudén E, Steegmann JL. Llamas-Velasco M, et al. Among authors: steegmann jl. Dermatol Ther. 2020 Nov;33(6):e14428. doi: 10.1111/dth.14428. Epub 2020 Nov 3. Dermatol Ther. 2020. PMID: 33073453
108 results